Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Gilead sciences, inc. crawled time : 19:00 save search
Gilead Sciences Publishes 2023 ESG Impact Report
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
gilead report sciences impact esg
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-03-21 (Crawled : 19:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.08%
H: 0.66%
C: -0.48%
yescarta t-cell treatment therapy
Kite Completes Acquisition of Tmunity
Published: 2023-02-22 (Crawled : 19:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.01%
H: 0.14%
C: -1.34%
acquisition
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
Published: 2023-02-03 (Crawled : 19:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 4.01%
H: 2.73%
C: -0.18%
trodelvy fda breast cancer her2 metastatic breast cancer
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
Published: 2022-12-12 (Crawled : 19:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.14%
H: 0.81%
C: 0.79%
yescarta ongoing lymphomas t-cell therapy
Pediatric Health Market Research Report by Type, Therapeutics, Treatment, Treatment Type, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-11-03 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.02%
H: 0.43%
C: 0.43%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -1.02%
H: 2.67%
C: 0.18%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.28%
H: 0.0%
C: 0.0%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.83%
H: 1.33%
C: -0.51%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.13%
H: 0.63%
C: 0.53%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.97%
H: 0.18%
C: -2.13%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.42%
H: 0.59%
C: -0.04%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 1.43%
H: 0.41%
C: 0.25%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.05%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.4%
H: 2.75%
C: 1.52%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.72%
H: 1.29%
C: 1.04%
covid-19 treatment research global report impact health market
HIV-Positive Consumer Joins Lawsuit Against Pharmaceutical Giant Gilead Over Price Gouging, says Consumer Watchdog
Published: 2022-09-26 (Crawled : 19:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.14%
H: 1.75%
C: 0.32%
hiv
Global Pulmonary Arterial Hypertension Drug Market to Surpass US$ 11,220.2 Million by 2030 - Coherent Market Insights
Published: 2022-09-13 (Crawled : 19:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -4.98%
H: 7.63%
C: 2.67%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.55%
H: 0.42%
C: -0.72%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.6%
H: 0.41%
C: -0.76%
UTHR | $237.99 0.45% 0.45% 400K
|
Health Technology
|
| O: 0.63%
H: 0.81%
C: 0.57%
MNKD | $4.19 2.7% 2.63% 1.8M
|
Health Technology
|
| O: 0.0%
H: 5.91%
C: 3.67%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.06%
H: 1.63%
C: 1.2%
drug global hypertension market
Disease-Modifying Antirheumatic Drug (DMARD) Market to Surpass US$ 27,167.8 Million by 2030 - Coherent Market Insights
Published: 2022-09-06 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.02%
H: 0.0%
C: 0.0%
UCBJY | $63.676 -4.38% 7.2K
|
Manufacturing
|
| O: 0.73%
H: 2.28%
C: 1.72%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.65%
H: 0.93%
C: 0.71%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.03%
H: 1.18%
C: 0.13%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.03%
H: 1.08%
C: 0.84%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.44%
H: 2.03%
C: 1.76%
CPIX | $1.65 6.02% 790
|
Health Technology
|
| O: -4.52%
H: 7.12%
C: 5.69%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.24%
H: 1.04%
C: 0.82%
drug market
Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration
Published: 2022-03-02 (Crawled : 19:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.3%
H: 1.76%
C: 1.32%
multi-year bay collaboration
Gilead Sciences to Present at Upcoming Investor Conferences
Published: 2021-02-18 (Crawled : 19:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.37%
H: 0.93%
C: 0.57%
conference presentation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.